Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
Trinity Biotech plc (TRIB) to announce financial results for Q4 and fiscal year 2023 on April 4, 2024. Conference call scheduled for 8:00 AM ET.
03/28/2024 - 06:39 PM
Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ET
DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET.
Conference Call Dial-In & Webcast Information
About Trinity Biotech www.trinitybiotech.com
When will Trinity Biotech plc (TRIB) announce financial results for Q4 and fiscal year 2023?
Trinity Biotech plc (TRIB) will announce financial results for Q4 and fiscal year 2023 on April 4, 2024.
What time is the conference call scheduled for on April 4, 2024?
The conference call is scheduled for 8:00 AM ET on April 4, 2024.
What is the Conference ID for the call?
The Conference ID for the call is 13745604.
Where can I access the webcast for the conference call?
You can access the webcast for the conference call by clicking on the provided link.
TRIB Rankings
#4935 Ranked by Stock Gains
TRIB Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
Ireland
City
Bray
About TRIB
since its formation in 1992, trinity biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products. the test kits manufactured by trinity biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune and haemoglobin disorders, and detect, monitor and control diabetes. the company is also a significant provider of raw materials to the life sciences industry. trinity biotech, which has its headquarters in ireland, employs in excess of 350 people and markets its portfolio of over 400 products to customers in 80 countries around the world. it reaches this worldwide market by combining the
